[1] 徐震纲, 刘绍严.分化型甲状腺癌颈侧区淋巴结清扫专家共识(2017版)[J].中国实用外科杂志, 2017, 9:985-991. DOI:10.19538/j.cjps.issn1005-2208.2017.09.13.
Xu ZG, Liu SY. Experts consensus on lymphadenectomy of lateral region of neck in differentiated thyroid carcinoma(2017)[J]. Chin J Pract Surg, 2017, 9:985-991. DOI:10.19538/j.cjps.issn1005-2208. 2017.09.13.
[2] 朱晓丽, 周晓燕, 孙团起, 等.甲状腺乳头状癌形态学变型与预后的关系[J].临床与实验病理学杂志, 2010, 26(5):560-565. DOI:10.13315/j.cnki.cjcep.2010.05.029.
Zhu XL, Zhou XY, Sun TQ, et al. Relationship of morphologic variants of papillary thyroid carcinoma and the prognosis[J]. J Clin Exp Pathol, 2010, 26(5):560-565. DOI:10.13315/j.cnki.cjcep.2010.05.029.
[3] Gu WJ, Yan HX, Luo YK, et al. Characterization of papillary thyroid microcarcinomas using sonographic features in malignant papillary thyroid cancer:a retrospective analysis[J]. Medicine (Baltimore), 2015, 94(21):e841. DOI:10.1097/MD.0000000000000841.
[4] 闫国珍, 刘扬, 袁彦芬, 等. 58例甲状腺滤泡状腺癌彩色超声及造影检查特征分析[J].包头医学院学报, 2016, 32(3):22-24. DOI:10.16833/j.cnki.jbmc.2016.03.009.
Yan GZ, Liu Y, Yuan YF, et al. The Contrast Study on the Contrast-enhanced Ultrasonography in the patients with medullary carcinoma of thyroid gland[J]. J Baotou Med Coll, 2016, 32(3):22-24. DOI:10.16833/j.cnki.jbmc.2016.03.009.
[5] 魏玺, 王晓庆, 王猛, 等.细针穿刺活检结合分子检测在甲状腺结节鉴别诊断中的研究进展[J].中国肿瘤临床, 2018, 45(1):33-36. DOI:10.3969/j.issn.1000-8179.2018.01.871.
Wei X, Wang XQ, Wang M, et al. Combination of ultrasound guided fine needle aspiration biopsy and molecular analysis for the differential diagnosis of thyroid nodules[J]. Chin J Clin Oncol, 2018, 45(1):33-36. DOI:10.3969/j.issn.1000-8179.2018.01.871.
[6] 何燕莲, 余岳芬, 徐小兰, 等.超声造影联合声辐射力脉冲成像技术在甲状腺微小乳头状癌诊断中的研究[J].中国临床医学影像杂志, 2018, 29(4):250-253, 262.  doi: 10.3969/j.issn.1008-1062.2018.04.006
He YL, Yu YF, Xu XL, et al. Study of contrast-enhanced ultrasound combined with acoustic radiation force impulse-imaging in the diagnosis of papillary thyroid micro-carcinoma[J]. J Chin Clin Med Imaging, 2018, 29(4):250-253, 262.  doi: 10.3969/j.issn.1008-1062.2018.04.006
[7] Mancini M, Greco A, Salvatore G, et al. Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice[J]. BMC Med Imaging, 2013, 13:31. DOI:10.1186/1471-2342-13-31.
[8] Aydın H, Kızılgöz V, Tatar Ï, et al. The role of proton MR spectroscopy and apparent diffusion coefficient values in the diagnosis of malignant thyroid nodules:preliminary results[J]. Clin Imaging, 2012, 36(4):323-333. DOI:10.1016/j.clinimag.2011. 09.009.
[9] 苏宇, 高思佳, 曹际斌, 等. IVIM理论中各参数值在甲状腺良恶性结节方面的鉴别诊断价值[J].中国临床医学影像杂志, 2017, 28(3):176-179. DOI:10.3969/j.issn.1008-1062.2017.03.007.
Su Y, Gao SJ, Cao JB, et al. Each parameter value in differential diagnosis of benign and malignant thyroid nodules under IVIM theoretical aspects[J]. J Chin Clin Med Imaging, 2017, 28(3):176-179. DOI:10.3969/j.issn.1008-1062.2017.03.007.
[10] 孙文伟, 魏丽琴, 侯洁, 等. 99mTcO4-/99mTc-MIBI联合显像对甲状腺癌的诊断价值[J].吉林大学学报(医学版), 2010, 36(4):783-786, 封3. DOI:10.13481/j.1671-587x.2010.04.054.
Sun WW, Wei LQ, Hou J, et al. Diagnosis value of 99mTcO4-/99mTc-MIBI combined with imaging in thyroid carcinoma[J]. J Jilin Univ(Medicine Edition), 2010, 36(4):783-786, back cover 3. DOI:10.13481/j.1671-587x.2010.04.054.
[11] Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J]. Thyroid, 2016, 26(1):1-133. DOI:10.1089/thy.2015.0020.
[12] 中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺癌血清标志物临床应用专家共识(2017版)[J].中国肿瘤临床, 2018, 45(1):7-13. DOI:10.3969/j.issn.1000-8179.2018.01.265.
[13] Trimboli P, Treglia G, Giovanella L. Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules:a systematic review[J]. Horm Metab Res, 2015, 47(4):247-252. DOI:10.1055/s-0034-1395517.
[14] Duccini K, de Souza MVL, Delfim R, et al. High Serum Thyrotropin Concentrations within the Reference Range:A Predictor of Malignancy in Nodular Thyroid Disease[J]. Med Princ Pract, 2018, 27(3):272-277. DOI:10.1159/000488196.
[15] 梅志丹, 陈晨, 胡章威, 等.甲状腺癌诊断及预后相关分子标志物的研究进展[J].现代生物医学进展, 2017, 17(18):3592-3595. DOI:10.13241/j.cnki.pmb.2017.18.045.
Mei ZD, Chen C, Hu ZW, et al. Progress in Molecular Markers of Thyroid Cancer Diagnosis, Prognosis[J]. Prog Mod Biomed, 2017, 17(18):3592-3595. DOI:10.13241/j.cnki.pmb.2017.18.045.
[16] Yang X, Li J, Li X, et al. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer[J]. J Nucl Med, 2017, 58(2):258-265. DOI:10.2967/jnumed.116.180240.
[17] Zhu G, Xie L, Miller D. Expression of MicroRNAs in Thyroid Carcinoma[J]. Methods Mol Biol, 2017, 1617:261-280. DOI:10.1007/978-1-4939-7046-9-19.
[18] 黄志刚, 陈晓红.分化型甲状腺癌个体化分层治疗的策略和意义[J].中华耳鼻咽喉头颈外科杂志, 2017, 52(6):405-409. DOI:10.3760/cma.j.issn.1673-0860.2017.06.002.
Huang ZG, Chen XH. The strategy and significance of individualized stratified therapy for differentiated thyroid carcinoma[J]. Chin J Otorhinolaryngol Head Neck Surg, 2017, 52(6):405-409. DOI:10.3760/cma.j.issn.1673-0860.2017.06.002.
[19] Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy[J]. Surgery, 2012, 151(4):571-579. DOI:10.1016/j.surg.2011.08.016.
[20] 郑向前, 候秀坤, 高明. 2017年第二版NCCN甲状腺肿瘤指南解读[J].中国肿瘤临床, 2018, 45(1):14-17. DOI:10.3969/j.issn.1000-8179.2018.01.046.
Zheng XQ, Hou XK, Gao M. Interpretation of the second edition of the NCCN guidelines for thyroid cancer in 2017[J]. Chin J Clin Oncol, 2018, 45(1):14-17. DOI:10.3969/j.issn.1000-8179. 2018. 01.046.
[21] 吴耀华.淋巴示踪技术在甲状腺癌手术中的应用[J].临床外科杂志, 2017, 25(11):832-834. DOI:10.3969/j.issn.1005-6483. 2017. 11.010.
Wu YH. Clinical application of lymphatic tracer technology to guide surgery for thyroid cancer[J]. J Clin Surg, 2017, 25(11):832-834. DOI:10.3969/j.issn.1005-6483.2017.11.010.
[22] 尚文婷, 田捷.纳米探针在肿瘤诊疗中的研究进展[J].中华核医学与分子影像杂志, 2017, 37(11):726-729. DOI:10.3760/cma.j.issn.2095-2848.2017.11.014.
Shang WT, Tian J. Progress of nanoprobes for cancer diagnosis and treatment[J]. Chin J Nucl Med Mol Imaging, 2017, 37(11):726-729. DOI:10.3760/cma.j.issn.2095-2848.2017.11.014.
[23] 吕国庆, 闫晶, 李冠, 等.载药纳米炭的淋巴化疗对小鼠结肠癌转移模型肿瘤细胞凋亡的影响[J].中国实验诊断学, 2012, 16(11):1994-1996. DOI:10.3969/j.issn.1007-4287.2012.11.012.
Lyu GQ, Yan J, Li G, et al. Research of lymphatic chemotherapy of drug loaded carbon nanoparticles to colonic carcinoma metastasis model in mice[J]. Chin J Lab Diagn, 2012, 16(11):1994-1996. DOI:10.3969/j.issn.1007-4287.2012.11.012.
[24] 瞿源, 黄蕤, 董萍, 等.低剂量和高剂量131I治疗中低危分化型甲状腺癌的随机对照研究[J].中华核医学与分子影像杂志, 2016, 36(5):384-388. DOI:10.3760/cma.j.issn.2095-2848.2016.05.002.
Qu Y, Huang R, Dong P, et al. Low-dose and high-dose 131I therapy for low and intermediate risk differentiated thyroid cancer:a randomized controlled clinical study[J]. Chin J Nucl Med Mol Imaging, 2016, 36(5):384-388. DOI:10.3760/cma.j.issn.2095-2848. 2016.05.002.
[25] 郑立春, 张腾, 胡厚洋, 等.非远处转移分化型甲状腺癌低剂量131I清甲治疗疗效分析[J].中华核医学与分子影像杂志, 2018, 38(3):160-163. DOI:10.3760/cma.j.issn.2095-2848.2018.03.00.
Zheng LC, Zhang T, Hu HY, et al. Ablation efficacy for non-distant metastases differentiated thyroid carcinoma with low-dose 131I[J]. Chin J Nucl Med Mol Imaging, 2018, 38(3):160-163. DOI:10.3760/cma.j.issn.2095-2848.2018.03.00.
[26] Kalender E, Zeki CY, Elboga U, et al. Lung metastases in patients with differentiated thyroid carcinoma and evaluation of response to radioiodine therapy[J]. Rev Esp Med Nucl Imagen Mol, 2012, 31(6):328-331. DOI:10.1016/j.remn.2012.04.007.
[27] 邱忠领, 许艳红, 宋红俊, 等. 131I治疗分化型甲状腺癌骨转移的疗效评价和生存分析[J].中华核医学杂志, 2011, 31(3):155-159. DOI:10.3760/cma.j.issn.0253-9780.2011.03.00.
Qiu ZL, Xu YH, Song HJ, et al. Evaluation of 131I treatment efficacy and prognostication for bone metastases from differentiated thyroid cancer[J]. Chin J Nucl Med, 2011, 31(3):155-159. DOI:10.3760/cma.j.issn.0253-9780.2011.03.00.
[28] Kim MK, Yun KJ, Kim MH, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma[J]. Bone, 2015, 71:101-105. DOI:10.1016/j.bone.2014.10.009.
[29] 叶丽姿, 乐岭.分化型甲状腺癌的药物治疗进展[J].医学研究生学报, 2018, 31(5):544-549. DOI:10.16571/j.cnki.1008-8199. 2018.05.021.
Ye LZ, Yue L. Progress of clinical medication for differentiated thyroid carcinoma[J]. J Med Postgra, 2018, 31(5):544-549. DOI:10.16571/j.cnki.1008-8199.2018.05.021.
[30] 郭晔, 梁军, 吕静, 等.碘难治性分化型甲状腺癌靶向药物不良反应管理专家共识(2018年版)[J].中国癌症杂志, 2018, 28(7):545-553. DOI:10.19401/j.cnki.1007-3639.2018.07.012.
Guo Y, Liang J, Lyu J, et al. Expert consensus on management for adverse reaction of targeted drugs of radioactive iodine-refractory differentiated thyroid cancer(2018)[J]. Chin Oncol, 2018, 28(7):545-553. DOI:10.19401/j.cnki.1007-3639.